ACTG

Business Context and Reporting Period

Company: Acacia Research Corporation (California Corporation)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 1995
Business Overview: The Company operates two segments: investment management (Acacia) and direct-mail distribution of health care products (subsidiary Whitewing Labs). The Company is no longer classified as a development stage entity due to significant revenues generated from the sale of its investment in Whitewing Labs.

Key Financial Metrics

Operating Cash Flow: Net cash used in operating activities was $(902,392) for the six months ended June 30, 1995, compared to $(439,809) in the prior year period. This usage was driven by increases in operating assets (inventories, prepaid expenses) despite net income.

Material Changes vs. Prior Period

• Profitability Shift: The Company transitioned from a net loss of $444,420 in the first half of 1994 to a net income of $117,207 in the first half of 1995. This reversal was primarily driven by a one-time gain of $611,343 from the sale of Whitewing Labs stock, which offset an operating loss of $487,116.
• Revenue Growth: Total sales increased 1,338% year-over-year for the six-month period, rising from $86,186 to $1,239,791. This growth is attributed to increased direct-mail and magazine advertising by the Whitewing Labs subsidiary.
• Balance Sheet Expansion: Total assets more than doubled from $1.24 million to $2.56 million. This increase was funded by the issuance of common stock, proceeds from the sale of Whitewing Labs equity, and a $350,000 investment in Acacia Capital Partners, L.P.
• Debt Reduction: A $200,000 convertible note payable outstanding at December 31, 1994, was extinguished by June 30, 1995.

Outlook, Risks, and Management Commentary

• Capital Requirements: Management states that future success depends on raising $25,000,000 in capital for Acacia Capital Partners, L.P. Without this investment, management fees may be insufficient to sustain operations, necessitating further equity financing.
• Revenue Concentration: Virtually all operating revenues are derived from the Whitewing Labs subsidiary. The investment management segment has not yet generated operating revenue.
• Legal Contingencies: Whitewing Labs is named in pending litigation regarding copyright, trademark infringement, and false representations. Management believes claims are without merit and covered by insurance.
• Future Operations: Whitewing Labs is in the process of making a public offering of its common stock. Management expects fees from the Acacia Capital Partners general partnership to increase significantly in 1996.

Investor Verification Checklist

• Sustainability of Earnings: Verify if the $611,343 gain on the sale of Whitewing Labs stock is a recurring revenue stream or a one-time event masking an underlying operating loss of $487,116.
• Cash Burn Rate: Confirm the company's ability to sustain operations given that operating activities consumed $902,392 in cash during the six-month period despite reported net income.
• Capital Raise Success: Monitor the progress of the $25,000,000 capital raise for Acacia Capital Partners, L.P., as failure to meet this target poses a significant risk to liquidity.
• Whitewing Labs IPO: Track the status of the subsidiary's planned public offering, which is a key component of the company's liquidity and growth strategy.
• Legal Exposure: Review the status of the pending litigation against Whitewing Labs to assess potential uninsured liabilities.